Please check your internet connection and try again.
# Sompraz HP (Pantoprazole Sodium)
## Overview
Pantoprazole sodium is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Reduction of the risk of NSAID-associated gastric ulcers in patients with a history of such ulcers who remain on NSAID treatment.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. A second 8-week course may be considered in patients who have not healed after the initial 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily.
* **Reduction of Risk of NSAID-Associated Gastric Ulcers:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally twice daily. Doses may be increased as needed. Doses greater than 40 mg twice daily should be administered with caution. The maximum recommended dose is 120 mg every 8 hours.
## Pediatric Dosing
Dosing in pediatric patients is variable and should be based on clinical judgment and specific protocols.
* **GERD (6 months to 16 years):** Typically 20 mg or 40 mg orally once daily, depending on weight and severity.
* Consult specific pediatric guidelines or product information for detailed dosing recommendations.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose is 40 mg orally once daily.
* **Renal Impairment:** No dose adjustment is typically necessary.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
Common adverse effects include: headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use of PPIs may be associated with an increased risk of fractures, Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** May decrease absorption of drugs such as ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole may inhibit CYP2C19, potentially increasing levels of drugs metabolized by this enzyme (e.g., clopidogrel, phenytoin).
## Monitoring
* Monitor for signs and symptoms of vitamin B12 deficiency and hypomagnesemia, especially with prolonged use.
* Monitor for effectiveness in healing esophagitis or reducing ulcer risk.
* Consider bone mineral density screening in patients at risk for osteoporosis.
## Clinical Pearls
* Pantoprazole HP is a delayed-release formulation. It should be swallowed whole and not chewed, cut, or crushed.
* Take at least 1 hour before a meal.
* Long-term use should be periodically reassessed for need.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information and consult with a qualified healthcare provider before making any treatment decisions.*
